Vertex Pharmaceuticals (VRTX) Leases (2009 - 2026)

Vertex Pharmaceuticals' Leases history runs 17 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• In Q1 2026, Leases rose 25.89% year-over-year to $1.7 billion; the TTM figure through Mar 2026 stood at $1.7 billion (up 25.89% YoY), while the FY2025 annual figure was $1.6 billion, up 15.18% from the prior year.
• Leases was $1.7 billion for Q1 2026 at Vertex Pharmaceuticals, up from $1.6 billion in the prior quarter.
• In the past five years, Leases ranged from a high of $1.7 billion in Q1 2026 to a low of $293.6 million in Q4 2023.
• Historically, Leases has averaged $805.7 million across 5 years, with a median of $342.7 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Leases dropped 21.14% in 2022, then jumped 362.13% in 2024.
• A 5-year view of Leases shows it stood at $315.5 million in 2022, then retreated by 6.94% to $293.6 million in 2023, then surged by 362.13% to $1.4 billion in 2024, then grew by 15.18% to $1.6 billion in 2025, then gained by 7.83% to $1.7 billion in 2026.
• The last three Leases figures came in at $1.7 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.